Your browser doesn't support javascript.
loading
Toxicological Properties of 7-Methylguanine, and Preliminary Data on its Anticancer Activity.
Kirsanov, Kirill; Fetisov, Timur; Antoshina, Elena; Trukhanova, Lubov; Gor'kova, Tatiana; Vlasova, Olga; Khitrovo, Irina; Lesovaya, Ekaterina; Kulbachevskaya, Nataliya; Shcherbakova, Tatiana; Belitsky, Gennady; Yakubovskaya, Marianna; Svedas, Vytas; Nilov, Dmitry.
Affiliation
  • Kirsanov K; Blokhin Cancer Research Center, Moscow, Russia.
  • Fetisov T; Peoples' Friendship University of Russia, Moscow, Russia.
  • Antoshina E; Blokhin Cancer Research Center, Moscow, Russia.
  • Trukhanova L; Blokhin Cancer Research Center, Moscow, Russia.
  • Gor'kova T; Blokhin Cancer Research Center, Moscow, Russia.
  • Vlasova O; Blokhin Cancer Research Center, Moscow, Russia.
  • Khitrovo I; Blokhin Cancer Research Center, Moscow, Russia.
  • Lesovaya E; Blokhin Cancer Research Center, Moscow, Russia.
  • Kulbachevskaya N; Blokhin Cancer Research Center, Moscow, Russia.
  • Shcherbakova T; Pavlov Ryazan State Medical University, Ryazan, Russia.
  • Belitsky G; Blokhin Cancer Research Center, Moscow, Russia.
  • Yakubovskaya M; Belozersky Institute of Physicochemical Biology, Lomonosov Moscow State University, Moscow, Russia.
  • Svedas V; Blokhin Cancer Research Center, Moscow, Russia.
  • Nilov D; Blokhin Cancer Research Center, Moscow, Russia.
Front Pharmacol ; 13: 842316, 2022.
Article in En | MEDLINE | ID: mdl-35873588
7-Methylguanine (7-MG) competitively inhibits the DNA repair enzyme poly(ADP-ribose) polymerase (PARP) and RNA-modifying enzyme tRNA-guanine transglycosylase (TGT) and represents a potential anticancer drug candidate. Furthermore, as a natural compound, it could escape the serious side effects characteristic for approved synthetic PARP inhibitors. Here we present a comprehensive study of toxicological and carcinogenic properties of 7-MG. It was demonstrated that 7-MG does not induce mutations or structural chromosomal abnormalities, and has no blastomogenic activity. A treatment regimen with 7-MG has been established in mice (50 mg/kg per os, 3 times per week), exerting no adverse effects or changes in morphology. Preliminary data on the 7-MG anticancer activity obtained on transplantable tumor models support our conclusions that 7-MG can become a promising new component of chemotherapy.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Front Pharmacol Year: 2022 Document type: Article Affiliation country: Rusia Country of publication: Suiza

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Front Pharmacol Year: 2022 Document type: Article Affiliation country: Rusia Country of publication: Suiza